Advertisement
Share

Novo Nordisk, Genentech Settle Lawsuit

Bloomberg News

Novo Nordisk, the world’s largest maker of diabetes treatments, and Genentech Inc., one of the world’s biggest biotech companies, said they settled a patent infringement dispute. Under the settlement, Novo Nordisk and Genentech will cross-license certain patents worldwide relating to human growth hormone, and Novo Nordisk will receive a worldwide license under Genentech patents relating to insulin for which Genentech will receive undisclosed payments. The agreement ends a legal battle that’s dragged on for more than four years and paves the way for Novo Nordisk of Denmark to enter the $500-million-a-year U.S. market for human growth hormones. The U.S. market is now dominated by South San Francisco-based Genentech and Eli Lilly & Co. of Indianapolis, said Charles Engelberg, an analyst with Americal Securities. Genentech officials weren’t immediately available for comment. Genentech shares rose 75 cents to close at $68.13 on the New York Stock Exchange.


Advertisement